Earnings summaries and quarterly performance for Monte Rosa Therapeutics.
Executive leadership at Monte Rosa Therapeutics.
Board of directors at Monte Rosa Therapeutics.
Research analysts covering Monte Rosa Therapeutics.
Recent press releases and 8-K filings for GLUE.
Monte Rosa Therapeutics prices underwritten public offering
GLUE
- Monte Rosa Therapeutics priced an underwritten public offering of 11,125,000 shares of common stock at $24.00 per share and 1,375,000 pre-funded warrants at $23.9999 per pre-funded warrant.
- The offering is expected to generate approximately $300 million in gross proceeds for Monte Rosa, excluding any exercise of the underwriters' option to purchase additional shares.
- The offering is anticipated to close on or about January 12, 2026.
Jan 9, 2026, 3:49 AM
Monte Rosa Therapeutics Announces Proposed Public Offering
GLUE
- Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE) has commenced an underwritten public offering of $200.0 million of shares of its common stock and pre-funded warrants to purchase shares of common stock.
- Monte Rosa also plans to grant the underwriters a 30-day option to purchase up to an additional $30.0 million of shares of its common stock.
- The offering is being managed by Jefferies, TD Cowen, and Piper Sandler as joint book-running managers.
- The proposed offering is subject to market and other conditions, and there is no assurance as to its completion, actual size, or terms.
Jan 7, 2026, 9:01 PM
Monte Rosa Therapeutics announces positive interim Phase I results for MRT-8102 in ASCVD
GLUE
New Projects/Investments
Guidance Update
- Monte Rosa Therapeutics reported positive interim results from its phase I study of MRT-8102, a NEK7-directed molecular glue degrader for atherosclerotic cardiovascular disease (ASCVD), showing no safety concerns in single ascending dose (SAD) and multiple ascending dose (MAD) cohorts.
- The study demonstrated a rapid and compelling reduction in high-sensitivity C-reactive protein (hsCRP), with an 85% sustained reduction observed in high CVD risk subjects after four weeks of dosing, and 94% of subjects achieving hsCRP levels below 2 mg/L. A 31% reduction in fibrinogen was also noted after four weeks of dosing.
- The company is expanding its phase I study, now named G-Force One, to explore additional dose levels and plans to initiate a phase II study (G-Force Two) for MRT-8102 in ASCVD in 2026.
- Data from the expanded G-Force One study are anticipated in the second half of 2026.
- Monte Rosa also highlighted progress in other pipeline programs, including MRT-6160 (licensed to Novartis) progressing to multiple phase II studies in immune-mediated diseases in 2026, and plans to initiate a phase II study for MRT-2359 in prostate cancer in 2026.
Jan 7, 2026, 1:00 PM
Monte Rosa Therapeutics Announces Positive Interim Phase I Results for MRT-8102 and Expansion of Clinical Program
GLUE
New Projects/Investments
- Monte Rosa Therapeutics announced that interim results from its phase I study of MRT-8102, a NEK7-directed molecular glue degrader, exceeded expectations, showing a rapid and compelling reduction in hsCRP and a 31% reduction in fibrinogen after four weeks of dosing in high CVD risk subjects.
- The study demonstrated a favorable safety profile for MRT-8102, with no serious adverse events and no evidence of increased infection risk across 112 subjects.
- The phase I study, now named GFORCE-1, will be expanded to explore additional dose levels, with data from this expanded study expected in the second half of 2026.
- Monte Rosa Therapeutics plans to initiate a phase II study, GFORCE-2, of MRT-8102 in ASCVD in 2026.
Jan 7, 2026, 1:00 PM
Monte Rosa Therapeutics Announces Positive Interim Phase I Results for MRT-8102
GLUE
New Projects/Investments
- Monte Rosa Therapeutics reported positive interim clinical results from its Phase I study of MRT-8102, a NEK7-directed molecular glue degrader, noting no safety concerns and a favorable safety profile across all cohorts as of the December 23, 2025 data cut-off.
- In subjects at high cardiovascular disease (CVD) risk, MRT-8102 demonstrated an 85% sustained reduction in high-sensitivity C-reactive protein (hsCRP) after four weeks of dosing, with 94% of subjects achieving hsCRP levels below 2 milligrams per liter. A 31% reduction in fibrinogen was also observed.
- The company is expanding the Phase I study, now named G-Force One, to include additional dose exploration of MRT-8102 in subjects with elevated CVD risk to accelerate development in atherosclerotic cardiovascular disease (ASCVD).
- Data from the expanded G-Force One study are expected in the second half of 2026, and a Phase II study (G-Force Two) of MRT-8102 in ASCVD is planned for 2026.
Jan 7, 2026, 1:00 PM
Monte Rosa Provides Update on MRT-8102 Phase 1 Study Results
GLUE
New Projects/Investments
- GLUE's MRT-8102, a NEK7-directed molecular glue degrader, demonstrated rapid and compelling reduction in hsCRP across all doses tested in healthy volunteers and high-CVD risk subjects, with no adverse safety signals observed as of December 23, 2025.
- Completed SAD and MAD cohorts showed ~80-90% NEK7 degradation in T cells at all dose levels and a 78% reduction in hsCRP in subjects with elevated baseline CRP levels.
- Preliminary data from the ongoing Part 3 (CRP PoC) of the Phase 1 study in high-risk CVD subjects indicated an 85% sustained reduction of hsCRP through week 4, with 94% of subjects achieving hsCRP levels below 2 mg/L and a 31% reduction of fibrinogen after 4 weeks of dosing.
- The study, now named GFORCE-1, will be expanded for accelerated development in ASCVD, with data expected in H2 2026, and plans to initiate the Phase 2 GFORCE-2 study in ASCVD in 2026.
Jan 7, 2026, 1:00 PM
Monte Rosa Therapeutics Announces Positive Interim Phase 1 Data for MRT-8102
GLUE
New Projects/Investments
- Monte Rosa Therapeutics, Inc. (GLUE) announced positive interim Phase 1 data for its NEK7-directed molecular glue degrader, MRT-8102, in subjects with elevated cardiovascular disease (CVD) risk.
- The data, with a cutoff of December 23, 2025, showed MRT-8102 reduced C-reactive protein (CRP) levels by 85% after four weeks of treatment, with 94% of participants achieving CRP values below 2 mg/L from a median baseline of 6.3 mg/L.
- A favorable safety profile was observed, characterized by mild to moderate adverse events and no evidence of increased infection risk.
- Monte Rosa plans to initiate a Phase 2 study for MRT-8102 in atherosclerotic cardiovascular disease (ASCVD) in 2026, with additional data from the GFORCE-1 study anticipated in H2 2026.
Jan 7, 2026, 12:06 PM
Monte Rosa Therapeutics Provides MRT-2359 Phase 1/2 Clinical Data Update
GLUE
New Projects/Investments
Guidance Update
- Monte Rosa Therapeutics announced positive interim Phase 1/2 clinical data for MRT-2359 in combination with enzalutamide for heavily pre-treated metastatic castration-resistant prostate cancer (mCRPC) patients.
- In 4 patients with AR mutations, MRT-2359 demonstrated compelling clinical activity, including a 100% disease control rate, with 4 patients showing PSA response (2 PSA90, 2 PSA50), and 2 patients achieving RECIST partial responses.
- The combination of MRT-2359 and enzalutamide was well tolerated, with mild or moderate manageable GI adverse events being the most frequent toxicities.
- The company plans to initiate a signal-confirming Phase 2 study of MRT-2359 in combination with a second-generation AR inhibitor in AR-mutated mCRPC patients in 2026. Updated data from the Phase 1/2 study are expected to be presented in February 2026.
Dec 16, 2025, 1:00 PM
GLUE Provides Update on MRT-2359 Program in Metastatic CRPC
GLUE
New Projects/Investments
- GLUE's MRT-2359 program in combination with enzalutamide demonstrated compelling clinical activity in heavily pretreated metastatic castration-resistant prostate cancer (CRPC) patients, particularly those with androgen receptor (AR) mutations.
- In the small subset of four AR mutant patients, the study observed a 100% PSA response rate and a 100% disease control rate as of the December 3rd data cutoff.
- The combination of MRT-2359 with enzalutamide was well tolerated, with mild or moderate manageable gastrointestinal adverse events being the most frequent toxicities.
- GLUE plans to initiate a signal-confirming phase II study in 2026 for MRT-2359 in combination with a second-generation AR inhibitor, initially focusing on up to 25 metastatic CRPC patients with AR mutations.
- The company also provided updates on other pipeline programs, including MRT-6160 (licensed to Novartis, progressing towards phase II studies) and MRT-8102 (interim phase I data expected in early 2026).
Dec 16, 2025, 1:00 PM
Monte Rosa Therapeutics Reports Positive Interim Clinical Results for MRT-2359 in Prostate Cancer
GLUE
New Projects/Investments
- Monte Rosa Therapeutics announced compelling interim clinical results from its Phase I/II study of MRT-2359 in combination with enzalutamide for heavily-pretreated metastatic castration-resistant prostate cancer (CRPC) patients.
- In the subset of four patients with androgen receptor (AR) mutations, MRT-2359 demonstrated a 100% PSA response rate (two PSA90, two PSA50) and a 100% disease control rate (two RECIST partial responses, two stable disease). Three of these four patients remained on therapy as of the December 3rd data cutoff.
- The combination of MRT-2359 with enzalutamide was well tolerated, with mild or moderate manageable gastrointestinal adverse events being the most frequent toxicities.
- The company plans to initiate a signal-confirming Phase II study for MRT-2359 in AR mutant CRPC patients in 2026, aiming to enroll up to 25 patients.
- Updated data from the Phase I/II study are expected to be presented at the ASCO Genitourinary Cancers Symposium in February 2026.
Dec 16, 2025, 1:00 PM
Quarterly earnings call transcripts for Monte Rosa Therapeutics.
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more